Now eligible for reimbursement from Medicare and Medicare Advantage! Learn More

Transformation begins with
Innovative Technology

Derived from your patient’s own blood, the ActiGraftPro® whole blood clot is applied directly to the wound bed where it regulates:

  • Wound pH levels
  • Provides growth factors
  • Red blood cells
  • Proteins
  • Minerals
  • Electrolytes
  • Dissolved gasses
  • Fibrin matrix

0 $
No Capital Equipment Required
5 min
Coagulation Time
28 cmsq
Versatile Sizing
72%
Complete wound closure rate*
*Based on 12 weeks of treatment

What makes ActiGraftPRO unique?

Proprietary patented technology utilizes nanoparticles to enable homogeneous activated whole blood, unlocking the healing power of this whole blood to manage challenging chronic non-healing wounds.

Personalized Care

Harnessing the body’s own natural resources, ActiGraftPro offers a personalized approach to healing unlike any other. Its adaptable size ensures a customized fit for any wound, with the capability to treat up to 56 sq. cm. in a single application.

The activated blood clot can be used with patients:

  • On blood thinners
  • With exposed bone and tendon

ActiGraftPro  is an inclusive solution for religiously or culturally sensitive patients, as it has no bovine, porcine, placental, or any other 3rd party products.

 

 

Natural Healing

The ActiGraftPro whole blood clot, derived from your patient’s own blood, replaces the dysfunctional ECM responsible for stalled wounds, with a functional ECM embedded with essential wound healing components/elements. Through this process, ActiGraftPro reactivates the innate wound healing process, facilitating natural healing cascade.

Streamlined Efficiency

Engineered with healthcare providers in mind.

ActiGraft Pro maximizes operational efficiency by eliminating the centrifuge, enabling ActiGraft whole blood clot preparation to 5 minutes or less, optimizing patient turnover.

Reliable Outcomes

Clinically proven by peer review published research and real-world case studies, ActiGraftPro delivers a 72% complete wound closure rate in 12 weeks.

ActiGraftPro system is described by the National Coverage Determination (NCD 270.3) as a blood-derived product and is eligible for reimbursement with HCPCS G0465.

ActiGraftPRO Preparation Procedure

In just a few simple steps, ActiGraft Pro is prepared at your patient’s point-of-care in 20 minutes or less.

Blood Draw

Draw 18 ml of your patient’s blood.

 Blood Transfer

Transfer whole blood into the coagulation mold (No centrifuging).

5-Minute Coagulation

Coagulation time can vary, but on average takes 5 minutes.

Direct Application

Remove the whole blood clot from its mold and apply it directly to your patient’s wound.

Trusted partner of leading American medical facilities and healthcare alliances.

Choose with confidence

Unlock Superior Wound Healing for Hard-to-Heal Wounds with ActiGraftPro that heals 2.83 times faster than standard of care.

Newly published data from a multicenter randomized controlled trial in diabetic foot ulcers confirms ActiGraftPro provides greater odds of reaching complete wound closure by week 12 compared to standard of care.1


Reference:
1Snyder R, Nouvong A, Ulloa J, Wahab N, Treadwell T, Bruwer F, Naude L, McGuire J, Reyzelman AM, Graham T; AWBC Research Team:; Lessing R, Lullove E, Ozker E, Pham HT, Pasternac M, Cohen S. Efficacy and safety of autologous whole blood clot in diabetic foot ulcers: a randomised controlled trial. J Wound Care. 2024 Sep 2;33(9):688-700. doi: 10.12968/jowc.2024.0195. Epub 2024 Aug 30. PMID: 39287414.

Resources

Videos

Video Thumbnail
Play
RedDress: Healing is in Our Blood
Video Thumbnail
Play
ActiGraft Procedure demonstration
Video Thumbnail
Play
ActiGraft Flowable Procedure
Video Thumbnail
Play
Healing is in Our Blood: Shaping the Future of Wound Care with Autologous Blood-Derived Products

Contact Us

Call us or email us for customer service.

+1-800-674-9615
customerservice@reddressmedical.com

Now eligible for reimbursement with Medicare and Medicare Advantage Plans

ActiGraftPro is described by the National Coverage Determination (NCD 270.3) as a blood-derived product for non-healing wounds and is eligible for reimbursement nationally from Medicare and Medicare Advantage.